PI3Kα targeting, nipping pancreatic cancer evolution in the bud.
| Autor: | Raja Arul GL; Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN, USA.; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN, USA., Fernandez-Zapico ME; Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | EMBO molecular medicine [EMBO Mol Med] 2021 Jul 07; Vol. 13 (7), pp. e14362. Date of Electronic Publication: 2021 May 31. |
| DOI: | 10.15252/emmm.202114362 |
| Abstrakt: | Thibault et al (2021) elucidate key signalling events mediating metastatic evolution in pancreatic ductal adenocarcinoma (PDAC) by demonstrating a role of PI3Kα in the regulation of macro-metastatic disease and a corresponding pro-tumoural immune response supporting disease progression. (© 2021 Mayo Clinic. Published under the terms of the CC BY 4.0 license.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Plný text